August 2, 2017 10:24 AM EDT

Ocular cuts staff in wake of FDA slapdown; Biogen recruits Pfizer vet; X4 inks discovery deal with Yale

Shehla Shakoor

Managing Director

→ Just days after its bid to salvage its second application for the drug/device eye therapy Dextenza failed with another slapdown by regulators, the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ocular cuts staff in wake of FDA slapdown; Biogen recruits Pfizer vet; X4 inks discovery deal with Yale

Shehla Shakoor

Managing Director

Sign up to read this article for free.

CagriSema’s weight loss data disappointed. What does Novo do next?

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Oc­u­lar cuts staff in wake of FDA slap­down; Bio­gen re­cruits Pfiz­er vet; X4 inks dis­cov­ery deal with Yale

Shehla Shakoor

Managing Director

Sign up to read this article for free.

more like this

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Ocular cuts staff in wake of FDA slapdown; Biogen recruits Pfizer vet; X4 inks discovery deal with Yale

CagriSema’s weight loss data disappointed. What does Novo do next?

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings